News

Cupron® Introduces Revolutionary, Cost-effective Antimicrobial Technology, Cupron Sinerji™

Cupron®, a renowned antimicrobial solutions provider – doing business as Cupron Performance Additives – is excited to announce the significant expansion of its offerings with the introduction of Cupron Sinerji™. This new adjuvant-enhanced platform offers superior antimicrobial efficacy across multiple substrates, all while maintaining an economical cost structure.

Cupron Sinerji incorporates adjuvants into the copper-based formulation, resulting in a custom, flexible technology engineered to harness synergistic effects to meet a wide range of product protection and antimicrobial performance objectives – from US EPA Treated Article Exemptions to unique and differentiated Public Health Claims.

Utilizing adjuvants, the technology delivers heightened efficacy against various organisms, improves color selection, and increases manufacturing yields. It offers an efficient and adaptable solution for numerous markets and applications, demonstrating its versatility and innovative potential across all polymers and organisms.

“The high prices of silver additives have previously compelled many brands to restrict their use in product manufacturing, subsequently diminishing the antimicrobial potency of the final products,” said Chris Andrews, CEO of Cupron Performances Additives. “However, Cupron Sinerji’s competitive cost to performance ratio is set to revolutionize traditional views on the value of antimicrobial solutions, introducing them to new applications that were previously considered cost-prohibitive.”

Cupron Sinerji has an attractive sustainability profile as the foundation of the platform is recycled copper and the technology is non-leaching. As a recognized micronutrient, copper presents a benign regulatory profile unlike other metal-ion (e.g. silver) or organic (e.g. ZnPT, PHMB, IPBC, etc.) alternatives under scrutiny in the marketplace.

Cupron Performance Additives is engaged with current sales and distribution partners to make the Cupron Sinerji technology platform available to their customers, and will add additional partners seeking to bring new additives to the commercial and industrial sectors.

 

Learn more here.

Recent News

11/21/2025

A new era of global growth: George Mason and Naugen launch international innovation accelerator

This month, a new Northern Virginia International Soft-Landing Accelerator (NISA) program, designed to help start-ups from around the globe find guidance, connections, and lab or office spaces at no cost, was launched to help develop new technologies in life sciences.Applications are now open for the first NISA cohort. Participants in the six-month program will have

11/20/2025

VIPC Signs MOU with AstraZeneca, Eli Lilly, Merck to Develop the Virginia Center for Advanced Pharmaceutical Manufacturing to Train Workforce of the Future

A Memorandum of Understanding (MOU) signed by the Virginia Innovation Partnership Corporation (VIPC) and AstraZeneca, Eli Lilly (Lilly), and Merck to develop the Virginia Center for Advanced Pharmaceutical Manufacturing (APM) was executed by Governor Glenn Youngkin at a statewide gathering with key leaders from Virginia’s life sciences ecosystem, higher-ed universities, and community colleges on October 31. This

11/11/2025

Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery Technologies

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the target loading concentrations for its two topical rapamycin delivery technologies have been successfully achieved. Specifically, a rapamycin loading concentration of 4% w/w has been achieved for Quoin’s proprietary topical